Table 1.
Quality assessment for the 17 included articles based on Newcastle–Ottawa quality assessment scale.
Selection |
Comparability |
Exposure |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
Refs. | Inclusion criteria | Sample size >50 | Endpoint | Anatomical location | Enneking stage | Chemotherapy | Local recurrence | 5-year overall survival | Metastatic | NOS |
Abudu et al. [12] | * | – | * | * | * | * | * | * | * | 8* |
Bacci et al. [13] | * | – | * | * | * | * | * | – | – | 6* |
Bacci et al.b[14] | * | * | * | – | – | * | * | * | * | 7* |
Bramer et al. [15] | * | * | * | * | – | * | * | – | – | 6* |
Ferguson et al. [16] | * | – | * | * | – | * | * | – | – | 5* |
Guo et al. [17] | * | – | * | * | – | * | * | – | * | 6* |
Hegyi et al. [18] | * | * | * | – | – | * | * | * | * | 7* |
Jiang et al. [19] | * | * | * | * | * | * | * | – | – | 8* |
Kim et al. [20] | * | – | * | * | – | * | * | – | – | 5* |
Ma et al. [21] | * | * | * | * | – | * | – | * | – | 6* |
Mavrogenis et al. [22] | * | – | * | * | – | * | * | – | * | 6* |
Niu et al. [23] | * | – | * | * | * | * | * | * | * | 8* |
Robert et al. [24] | * | * | * | * | – | – | * | * | – | 6* |
Scully et al. [25] | * | * | * | * | * | * | * | * | – | 8* |
Xu et al. [26] | * | * | * | * | * | * | * | * | – | 8* |
Zhang et al. [27] | * | – | * | * | * | * | * | – | * | 7* |
Zhao et al. [28] | * | * | * | * | * | * | * | – | – | 7* |